<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03700450</url>
  </required_header>
  <id_info>
    <org_study_id>Allo-MM-PostCy-Study</org_study_id>
    <nct_id>NCT03700450</nct_id>
  </id_info>
  <brief_title>Cyclophosphamide as Graft-versus-host Prophylaxis After Allogeneic Stem Cell Transplantation for Multiple Myeloma</brief_title>
  <official_title>Cyclophosphamide as Graft-versus-host Prophylaxis After Allogeneic Stem Cell Transplantation for Multiple Myeloma. A Phase II Study (Allo-MM-PostCy-Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Riemser</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical Trial Center North (CTC North GmbH &amp; Co. KG)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study is a multicenter, prospective phase II-study to evaluate the chronic GvHD
      and progression-free survival at 2 years after after allogeneic stem cell transplantation for
      patients with multiple myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present study is a multicenter, prospective Phase II-study to evaluate the incidence of
      acute and chronic graft-versus-host disease at 2-years, the 2-year risk of non-relapse
      mortality, the 2-year progressive-free, and overall survival in patients with multiple
      myeloma who received a toxicity-reduced conditioning regimen combined of thiotepa and
      busulfan followed by allogeneic stem cell transplantation from matched or mismatched,
      related/unrelated and haploidentical donor, and cyclophosphamide as post-transplant GvHD
      prophylaxis in comparision to a historical group.

      In this study will further determine toxicity and safety of cyclophosphamide as GvHD
      prophylaxis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 16, 2018</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All patients will receive on day 3 and 4 after allogeneic stem cell transplan-tation 50 mg/kg BW cyclophosphamide</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Chronic GvHD</measure>
    <time_frame>2 years</time_frame>
    <description>Chronic GvHD at 2 years after allogeneic SCT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>Progression-free survival at 2 years after allogeneic SCT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non-relapsed mortality</measure>
    <time_frame>2 years</time_frame>
    <description>Non-relapsed mortality at 2 years after allogeneic SCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute GvHD</measure>
    <time_frame>Day +100 after allogeneic SCT</time_frame>
    <description>Incidence of acute GvHD on Day +100 after allogeneic SCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic GvHD</measure>
    <time_frame>1 and 2 years after allogeneic SCT</time_frame>
    <description>Incidence of chronic GvHD at 1 and 2 years after allogeneic SCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>till 2 years</time_frame>
    <description>Toxicity scored according to NCI CTCAE, Version 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission</measure>
    <time_frame>till 2 years</time_frame>
    <description>Complete remission rate (including sCR and MRD negativity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Overall survival at 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Progression-free survival at 2 years</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Cyclophosphamid post Tranplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive on day 3 and 4 after allogeneic stem cell transplantation 50 mg/kg BW cyclophosphamide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Patients will receive on day 3 and 4 after allogeneic stem cell transplantation 50 mg/kg BW cyclophosphamide</description>
    <arm_group_label>Cyclophosphamid post Tranplant</arm_group_label>
    <other_name>Endoxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Multiple myeloma newly diagnosed with deletion 17p or translocation 4;14 or multiple
             myelo-ma with 1. or 2. relapse after autologous stem cell transplantation

          2. Patients age: 18 - 65 years at time of inclusion (female and male)

          3. Performance status ECOG &lt; 2

          4. Availability of haploidentical, matched or mismatched relative or unrelated donor

          5. Patients understand and voluntarily sign an informed consent

          6. The study population includes female of childbearing potential (FOCP). FOCP have to
             agree to comply with the applicable contraceptive requirements of the protocol as
             named below for the duration of the study and 6 months after end of study or having
             post-menopausal status or be permanently sterilized (at least 6 weeks
             post-sterilization).

          7. Men who are sexually active with FOCP must be instructed to use male contraception
             (condom) in order to avoid exposure of an existing embryo/fetus. Contraception should
             be continued until 6 months after end of study.

        Exclusion Criteria:

          1. Severe active infection or other uncontrolled severe conditioning

          2. Severe renal, hepatic, pulmonary or cardiac disease, such as:

               -  Total bilirubin, SGPT or SGOT &gt; 3 times upper the normal level

               -  Left ventricular ejection fraction &lt; 30 %

               -  Creatinine clearance &lt; 30 ml/min

               -  DLCO &lt; 35 % and/or receiving supplementary continuous oxygen

          3. Positive serology for HIV

          4. Pregnant or lactating women (positive serum pregnancy test)

          5. Women of child-bearing potential with unclear contraception

          6. Age &lt; 18 and &gt; 65 years.

          7. Uncontrolled invasive fungal infection at time of screening (baseline)

          8. Serious psychiatric or psychological disorders

          9. Participation in another study with ongoing use of unlicensed investigational product
             from 28 days before study enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolaus Kröger, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Hamburg-Eppendorf</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolaus Kröger, Prof. Dr.</last_name>
    <phone>+49(0)40-7410-55864</phone>
    <email>n.kroeger@uke.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christine Wolschke, Dr.</last_name>
    <phone>+49(0)40-7410-54188</phone>
    <email>wolschke@uke.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolaus Kroeger, Prof. Dr.</last_name>
      <phone>+49-40-7410-55864</phone>
      <email>nkroeger@uke.de</email>
    </contact>
    <contact_backup>
      <last_name>Marion Heinzelmann</last_name>
      <phone>+49-40-7410-54188</phone>
      <email>mheinzel@uke.de</email>
    </contact_backup>
    <investigator>
      <last_name>Nicolaus Kröger, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine Wolschke, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ute Hegenbart, PD Dr.</last_name>
      <email>Ute.Hegenbart@med.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Ute Hegenbart, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefan Schönland, Prof. Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin der Johannes Gutenberg-Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Wagner-Drouet, Dr.</last_name>
      <email>eva.wagner@unimedizin-mainz.de</email>
    </contact>
    <investigator>
      <last_name>Eva Wagner-Drouet, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Markus Munder, PD Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 23, 2018</study_first_submitted>
  <study_first_submitted_qc>October 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2018</study_first_posted>
  <last_update_submitted>March 4, 2020</last_update_submitted>
  <last_update_submitted_qc>March 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Without detection of deletion 17p or translocation 4;14;</keyword>
  <keyword>Post Cyclophosphamide</keyword>
  <keyword>GvHD Prophylaxis</keyword>
  <keyword>Allogeneic SCT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

